OncoVee™-mini-patient-derived xenograft guided adjuvant chemotherapy treatment for resectable gastric cancer

doi:10.4251/wjgo.v18.i7.118050

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(4)

(5)

(0)

(27)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jul 15, 2026; 18(7): 118050
Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.118050

Table 1 Comparison of patient-derived xenograft and mini patient-derived xenograft for gastric cancer

	PDX	MiniPDX
Model establishment time (median days)¹	70-112	7
Modeling success rate	15.1%-35.5%	100%
Reference	[39-43]	[24]

¹The time required for modeling patient-derived xenograft, defined as the duration from the implantation of human-derived tumor tissue into the first generation of tumor-bearing mice (trans generation 1) until the passage to the second generation of tumor-bearing mice (trans generation 2), was measured in days.

PDX: Patient-derived xenograft; MiniPDX: Mini patient-derived xenograft.

Full Size Table

Table 2 Patients’ demographic and tumor characteristics, n (%)

Characteristics	All (n = 36)	MiniPDX group (n = 16)	Experimental treatment group (n = 20)	P value
Age, years, median (range)	58 (42-79)	55 (42-66)	60 (47-79)	0.438
Age, group				0.813
≤ 60 years	24 (66.67)	11 (68.75)	13 (65.00)
> 60 years	12 (33.33)	5 (31.25)	7 (35.00)
Gender				0.593
Male	22 (61.11)	9 (56.25)	13 (65.00)
Female	14 (38.89)	7 (43.75)	7 (35.00)
ECOG PS
0-1	36 (100)	16 (100)	20 (100)
2	0 (0)	0 (0)	0 (0)
T-stage of primary tumor¹				0.556
pT1	10 (27.78)	3 (18.75)	7 (35.00)
pT2	8 (22.22)	3 (18.75)	5 (25.00)
pT3	15 (41.67)	8 (50.00)	7 (35.00)
pT4	3 (8.33)	2 (12.50)	1 (5.00)
N-stage of primary tumor¹				0.400
N0	19 (52.78)	6 (37.50)	13 (65.00)
N1	6 (16.67)	4 (25.00)	2 (10.00)
N2	2 (5.56)	1 (6.25)	1 (5.00)
N3	9 (25.00)	5 (31.25)	4 (20.00)
M-stage¹
M0	36 (100)	16 (100)	20 (100)
M1	0 (0)	0 (0)	0 (0)
Stage of AJCC¹				0.095
I	16 (44.44)	4 (25.00)	12 (60.00)
II	9 (25.00)	6 (37.50)	3 (15.00)
III	11 (30.56)	6 (37.50)	5 (25.00)

¹Tumor stage was defined according to the American Joint Committee on Cancer tumor-node-metastasis staging system (8^th edition).

MiniPDX: Mini patient-derived xenograft; ECOG PS: Eastern Cooperative Oncology Group Performance Status; AJCC: American Joint Committee on Cancer.

Full Size Table

Table 3 Univariate and multivariate Cox proportional hazards regression analysis of recurrence-free survival

Characteristics	Mean recurrence-free survival months	P value	Multivariate adjusted hazard ratio (95% confidence interval)¹	P value
Treatment		0.025	0.266 (0.087-0.816)	0.021
MiniPDX group, n = 16	48.2 (37.9-58.5)
Experimental treatment group, n = 20	32.7 (23.7-41.7)
Age group		0.286	NA	NA
≤ 60, n = 24	42.0 (32.6-51.4)
> 60, n = 12	32.3 (22.8-41.7)
Sex		0.336	NA	NA
Male, n = 22	42.7 (33.6-51.7)
Female, n = 14	32.3 (21.9-42.7)
T-stage of primary tumor¹		0.100	NA	NA
pT1, n = 10	46.0 (33.6-58.3)
pT2, n = 8	49.1 (35.4-62.8)
pT3, n = 15	32.8 (22.5-43.0)
pT4, n = 3	15.7 (3.5-27.9)
N-stage of primary tumor¹		0.027	NA	NA
N0, n = 19	42.6 (32.5-52.8)
N1, n = 6	54.3 (40.6-68.1)
N2, n = 2	31.5 (0.0-67.8)
N3, n = 9	25.7 (13.3-38.1)
Stage of AJCC¹		0.018	NA	NA
Stage 1, n = 16	46.0 (35.8-56.2)		0.536 (0.330-0.869)²	0.011
Stage 2, n = 9	45.8 (30.8-60.8)		0.542 (0.349-0.840)³	0.06
Stage 3, n = 11	26.8 (15.6-38.0)		1.688⁴	0.194

¹Tumor stage was defined according to the American Joint Committee on Cancer tumor-node-metastasis staging system (8^th edition).

²Multivariate Cox analysis results for American Joint Committee on Cancer stage 1 vs stages 2 + 3 in subjects (stage 1, n = 16; stage 2 + 3, n = 20).

³Multivariate Cox analysis results for American Joint Committee on Cancer stage 1 + 2 vs stages 3 in subjects (stage 1 + 2, n = 25; stage 3, n = 11).

⁴Multivariate Cox analysis results for American Joint Committee on Cancer stage 2 vs stages 3 in subjects (stage 2, n = 9; stage 3, n = 11).

MiniPDX: Mini patient-derived xenograft; AJCC: American Joint Committee on Cancer; NA: Not available.

Full Size Table

Table 4 Univariate and multivariate Cox proportional hazards regression analysis of overall survival

Characteristics	Mean recurrence-free survival months	P value	Multivariate adjusted hazard ratio (95% confidence interval)¹	P value
Treatment		0.036	0.283 (0.081-0.997)	0.050
MiniPDX group, n = 16	54.5 (46.9-62.1)
Experimental treatment group, n = 20	43.5 (36.2-50.7)
Age group		0.312	NA	NA
≤ 60, n = 24	50.6 (43.6-57.5)
> 60, n = 12	42.8 (33.6-52.1)
Sex		0.078	NA	NA
Male, n = 22	52.1 (45.2-59.0)
Female, n = 14	39.1 (31.9-46.3)
T-stage of primary tumor¹		0.208	NA	NA
pT1, n = 10	50.3 (41.7-58.9)
pT2, n = 8	52.6 (42.0-63.2)
pT3, n = 15	45.1 (36.0-54.2)
pT4, n = 3	26.3 (18.0-34.6)
N-stage of primary tumor¹		0.465	NA	NA
N0, n = 19	48.3 (40.5-56.1)
N1, n = 6	55.7 (44.3-67.0)
N2, n = 2	45.5 (24.0-67.0)
N3, n = 9	40.0 (30.8-49.2)
Stage of AJCC¹		0.554	NA	NA
Stage 1, n = 16	51.3 (44.0-58.6)
Stage 2, n = 9	47.7 (34.5-60.8)
Stage 3, n = 11	42.4 (32.9-52.0)

¹Tumor stage was defined according to the American Joint Committee on Cancer tumor-node-metastasis staging system (8^th edition).

MiniPDX: Mini patient-derived xenograft; AJCC: American Joint Committee on Cancer; NA: Not available.

Full Size Table

Citation: Qiu YX, Jian KY, Xu QR, Lu X, Jia BL, Jiang L, Liang F. OncoVee™-mini-patient-derived xenograft guided adjuvant chemotherapy treatment for resectable gastric cancer. World J Gastrointest Oncol 2026; 18(7): 118050
URL: https://www.wjgnet.com/1948-5204/full/v18/i7/118050.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i7.118050

Qiu YX, Jian KY, Xu QR, Lu X, Jia BL, Jiang L, Liang F. OncoVee™-mini-patient-derived xenograft guided adjuvant chemotherapy treatment for resectable gastric cancer. World J Gastrointest Oncol 2026; 18(7): 118050 [DOI: 10.4251/wjgo.v18.i7.118050]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.